CeriBell (NASDAQ:CBLL) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

CeriBell (NASDAQ:CBLL) released its quarterly earnings data on Monday. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13), FiscalAI reports. The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.

CeriBell Stock Performance

CeriBell stock traded down $0.14 during trading hours on Monday, hitting $20.06. The stock had a trading volume of 306,852 shares, compared to its average volume of 307,145. The company has a 50-day moving average of $19.17 and a two-hundred day moving average of $18.71. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. CeriBell has a fifty-two week low of $10.85 and a fifty-two week high of $24.33. The company has a market cap of $759.71 million, a PE ratio of -13.65 and a beta of 0.99.

Analyst Ratings Changes

Several brokerages have commented on CBLL. Weiss Ratings reiterated a “sell (d-)” rating on shares of CeriBell in a report on Monday, April 6th. BTIG Research reaffirmed a “buy” rating and set a $30.00 price objective on shares of CeriBell in a report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.20.

Insider Buying and Selling at CeriBell

In related news, CEO Xingjuan Chao sold 39,000 shares of the business’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $20.10, for a total value of $783,900.00. Following the sale, the chief executive officer owned 836,347 shares of the company’s stock, valued at $16,810,574.70. The trade was a 4.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Josef Parvizi sold 16,714 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $20.27, for a total transaction of $338,792.78. Following the completion of the sale, the director owned 722,652 shares in the company, valued at $14,648,156.04. This represents a 2.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 175,119 shares of company stock worth $3,310,772 over the last three months. 20.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CeriBell

A number of hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its stake in shares of CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after acquiring an additional 854 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares in the last quarter. Royal Bank of Canada raised its position in CeriBell by 10.8% in the 4th quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock worth $342,000 after purchasing an additional 1,514 shares during the last quarter. Finally, Invesco Ltd. boosted its position in CeriBell by 15.5% in the 4th quarter. Invesco Ltd. now owns 12,037 shares of the company’s stock valued at $264,000 after buying an additional 1,618 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.